Drug intelligence / Profile preview

SPK004

Development stage: Preclinical
Lead developer: SpikImm
Modality: Monoclonal Antibodies → Antibody-Based Therapeutics

Overview

SPK004 is a monoclonal antibody developed by SpikImm that targets the VP1 capsid protein of both BK polyomavirus (BKPyV) and JC polyomavirus (JCPyV). By binding to the VP1 protein, the antibody neutralizes the virus and blocks its entry into host cells, thereby preventing or treating viral-associated complications. It is currently in preclinical development for BK virus-associated nephropathy (BKVAN) in kidney transplant recipients, BK virus-associated hemorrhagic cystitis in hematopoietic stem cell transplant (HSCT) patients, and progressive multifocal leukoencephalopathy (PML).

Targets

Norovirus VP1

Beyond the preview

Go deeper on SPK004.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on SPK004.